Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyAvMed Alpha Proteinase Inhibitors Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Alpha Proteinase Inhibitors (Medical)

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization policy for intravenous alpha-1 antitrypsin (AAT) augmentation therapy (Aralast NP, Glassia, Prolastin-C, Zemaira) including initial and continuation authorization clinical criteria, quantity limits (NDCs/HCPCS units), and administrative submission requirements for AvMed members.

    Policy Summary
    PayerAvMed
    PolicyAlpha Proteinase Inhibitors (Medical)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionPrescribers must complete and sign the AvMed medical prior authorization form and fax with all required documentation (labs, PFTs, chart notes) to 1-877-535-1391; incomplete information may delay or deny authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes.

    4Products listed
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Serum AAT threshold options
    12Authorization length (months)

    Coverage Summary

    This AvMed prior authorization policy applies to intravenous alpha-1 antitrypsin (AAT) augmentation therapy (products listed: Aralast NP, Glassia, Prolastin-C, Zemaira) and covers both initial and continuation authorizations for members receiving IV AAT for congenital AAT deficiency with emphysema. The policy defines clinical criteria that must be met for approval, quantity limits and unit billing per vial (NDC/HCPCS), and administrative submission requirements for prior authorization.

    The policy specifically addresses prior authorization requirements for initiation and continuation (each authorized for up to 12 months), including the clinical criteria and documentation that must be submitted to support approval.

    Key thresholds and facts
    FEV1 declineRate of decline in FEV1 documented between 30 and 65%
    Serum AAT level optionsOne of: < 11 µmol/L OR < 80 mg/dL (radial immunodiffusion) OR < 57 mg/dL (nephelometry)
    Authorization lengthInitial and continuation authorizations are for 12 months
    Products listedAralast NP, Glassia, Prolastin-C, Zemaira (4 products)

    Medical Necessity Criteria

    Not Covered / Experimental

    No explicit exclusions or experimental uses are listed in the brief beyond general risk of denial if required documentation is incomplete, illegible, or missing.

    Coding

    HCPCS codes listed for productsHCPCS
    J0256ARALAST NP, PROLASTIN-C, ZEMAIRA (listed for multiple products on form)
    J0257GLASSIA
    NDCs and unit billing per vialNDC
    00944-2815-01Aralast NP 1000 mg (1 vial) = 100 billable units
    00944-2814-01Aralast NP 500 mg (1 vial) = 50 billable units
    00944-2884-XXGlassia 1,000 mg/50 mL (1 vial) = 100 billable units
    13533-0705-XXProlastin-C 1,000 mg/20 mL (1 vial) = 100 billable units
    13533-0700-02Prolastin-C 1,000 mg (1 vial) = 100 billable units
    13533-0703-10Prolastin-C 1,000 mg (1 vial) = 100 billable units
    00053-7201-02Zemaira 1,000 mg (1 vial) = 100 billable units

    Provider Actions

    Prior Authorization

    Prior authorization required

    Prescribers must complete and sign the AvMed medical prior authorization form and fax it with all required documentation to 1-877-535-1391. The prescribing physician must sign and clearly print their name (preprinted stamps not valid).

    Documentation Required

    Submit phenotype and lab results

    Specify the member's AAT phenotype (e.g., PiZ, PiZ (null), Pi (null,null), PiMZ, PIMS). Submit serum AAT level with the date obtained and pulmonary function test results documenting FEV1 values and the documented rate of decline.

    Background

    The policy requires documentation to support each listed criterion; incomplete or missing documentation may delay or result in denial of authorization. Prescribers must complete and sign the AvMed prior authorization form and fax all required documentation (labs, pulmonary function tests, chart notes) to 1-877-535-1391.

    For initial authorization (up to 12 months), all of the following must be met and documented: diagnosis of congenital alpha-antitrypsin deficiency with emphysema; specification of the member's AAT phenotype (examples include PiZ, PiZ (null), Pi (null, null), PiMZ, PIMS); clinical evidence of progressive panacinar emphysema; member is a current non-smoker; documented rate of decline in FEV1 between 30 and 65% (submit pulmonary function test results); and a submitted serum AAT level (with result and date) that meets one of the following thresholds: < 11 µmol/L, < 80 mg/dL if measured by radial immunodiffusion, or < 57 mg/dL if measured by nephelometry.

    For continuation of therapy while insured with AvMed (up to 12 months), all of the following must be documented: member compliance with medication, demonstrated clinical improvement in the past 3 months, and submission of a serum AAT level with date and value. For continuation from another plan, initial authorization information plus required labs and chart notes must be submitted to establish continuity of care.

    Quantity limits and unit billing instructions require billing per listed billable units per vial (examples: 100 billable units per 1000 mg vial for most products) and use of the corresponding NDC when applicable.

    Definitions
    AATAlpha-1 antitrypsin (requires serum level submission)

    Medicare Determinations

    NameType/Number/Effective Date
    Medicare Coverage for outpatient (Part B) drugs
    Type: NCD (National Coverage Determination) — Number: (not specified) — Effective date: (not specified)

    Revision History

    Policy Summary
    PayerAvMed
    PolicyAlpha Proteinase Inhibitors (Medical)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionPrescribers must complete and sign the AvMed medical prior authorization form and fax with all required documentation (labs, PFTs, chart notes) to 1-877-535-1391; incomplete information may delay or deny authorization.
    SourceLink
    On This Page
    Coverage SummaryMedical Necessity CriteriaNot Covered / ExperimentalCodingProvider ActionsBackgroundMedicare DeterminationsRevision History
    Billing Rule

    Quantity limits and unit billing

    Bill per the listed billable units per vial (e.g., 100 units per 1000 mg vial; 50 units per 500 mg vial) and use the corresponding NDC when applicable.

    • 00944-2815-01
    • 00944-2814-01
    • 00944-2884-XX
    • 13533-0705-XX
    • 13533-0700-02
    • 13533-0703-10
    • 00053-7201-02
    Prior Authorization

    Initial and continuation authorization durations

    Initial authorization and continuation approvals are authorized for up to 12 months.

    Documentation Required

    Continuation from another plan

    For continuation of therapy from another plan, submit the prior plan's initial authorization information along with required labs and chart notes to establish continuity of care.

    Denial Risk

    Failure to provide documentation may result in denial

    Requests may be denied if required documentation (labs, diagnostics, chart notes) is not provided, incomplete, illegible, or missing.

    Billing Rule

    Administration site reporting

    Provide the location/site of drug administration and the NPI or DEA number of the administering location, or indicate that the medication is provided via the specialty pharmacy (Proprium Rx).

    FEV1Forced expiratory volume in 1 second (rate of decline in FEV1 must be documented)